Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:6/1/2010

eck cancers.

About REOLYSIN

REOLYSIN is a proprietary formulation of the human reovirus that acts primarily as a direct cytotoxic agent. Reovirus is naturally occurring (not genetically engineered) and has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway, leaving healthy normal cells intact. At least two thirds of carcinomas and more than 90% of metastatic disease has Ras involvement.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the FAMHP approval of a Phase 3 combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-refractory head and neck cancers, the planned timing and implementation of the Phase 3 trial, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
4. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
5. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
6. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
7. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
9. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
(Date:1/14/2014)... Independent publisher Bitingduck Press, with offices in Altadena ... ideas for 2014 in production and sales of interactive ... high-quality, low-cost, DRM-free ebooks and to use the sales ... first major development will be bookstore sales in local ...
Breaking Biology Technology:RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 21, 2011 MO BIO Laboratories, Inc., ... purification, announces the launch of the RTS DNase™ Kit, ... enzyme. (Photo: http://photos.prnewswire.com/prnh/20110921/LA65994 ) ... from RNA preparations while protecting valuable RNA samples from ...
... Silence Therapeutics plc (AIM: SLN) ("Silence", the "Group" or ... company, today announces the appointment of Tony Sedgwick PhD, ... Sedgwick will be based in Silence,s London office and ... Tony Sedgwick is an experienced biotechnology and pharmaceutical ...
... SANTA CRUZ, Calif., Sept. 20, 2011 SomaGenics, Inc., ... data on the efficacy of RNA interference (RNAi) therapeutics ... sshRNA platform. SomaGenics, along with its ... in a poster entitled "Synthetic Short shRNAs are Potent ...
Cached Biology Technology:MO BIO Laboratories, Inc. Launches the RTS DNase™ Kit 2Appointment of Chief Business Officer 2Appointment of Chief Business Officer 3SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 2SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus 3
(Date:4/23/2014)... shows Africa,s Congo rainforest, the second-largest tropical rainforest in ... over the past decade. , The study, led by ... New York, shows between 2000 and 2012 the decline ... The research, published Wednesday in Nature , is ... the effects of long-term drought on the Congo rainforest ...
(Date:4/23/2014)... to early fetal death according to a new study ... Hospital Los Angeles and Ulaanbaatar, Mongolia the coldest ... published today in the journal BMC Pregnancy and ... seasonal ambient air pollutants and pregnancy loss in Ulaanbaatar ... highest levels of air pollution of all world capitals, ...
(Date:4/23/2014)... Like a hungry diner ripping open a dinner roll, ... must tear open a hydrogen molecule. Now researchers have ... the two halves of its hydrogen feast. The view ... make the catalyst work better for alternative energy uses. ... shown precisely where the hydrogen halves end up in ...
Breaking Biology News(10 mins):NASA satellites show drought may take toll on Congo rainforest 2NASA satellites show drought may take toll on Congo rainforest 3Pollutants from coal-burning stoves strongly associated with miscarriages in Mongolia 2Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4
... researchers have shown natural radioactivity within DNA can alter ... The research, recently published in Biochimica et ... at natural radioactivity within human DNA on the atomic-scale. ... as well as in every living organism across the ...
... 2013 In the past decade, a single strain of ... become the main cause of bacterial infections in women and ... a study published today in the American Society for Microbiology,s ... resistant to antibiotics, the strain H30-Rx gained an unprecedented ability ...
... climate and biosphere modelling suggests that the length of time ... known as ,residence time, - is the key "uncertainty" in ... all life - will respond to higher CO2 levels and ... time in vegetation as the negative impacts of climate change ...
Cached Biology News:Radioactivity muddles the alphabet of DNA 2Epidemic of Escherichia coli infections traced to 1 strain of bacteria 2Epidemic of Escherichia coli infections traced to 1 strain of bacteria 34 degree rise will end vegetation 'carbon sink' 24 degree rise will end vegetation 'carbon sink' 3
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Rabbit polyclonal to KIAA1276 ( Abpromise for all tested applications). entrezGeneID: 27146 SwissProtID: Q9ULE4...
Phospho-Chk1 (Ser296) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Biology Products: